Does the media refer more to LAB or CYRX?

In the previous week, Standard BioTools and Standard BioTools both had 4 articles in the media. CryoPort's average media sentiment score of 0.26 beat Standard BioTools' score of 0.04 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LAB or DNA?

In the previous week, Ginkgo Bioworks had 16 more articles in the media than Standard BioTools. MarketBeat recorded 20 mentions for Ginkgo Bioworks and 4 mentions for Standard BioTools. Ginkgo Bioworks' average media sentiment score of 0.33 beat Standard BioTools' score of 0.04 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 6 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to LAB or MLAB?

In the previous week, Standard BioTools had 1 more articles in the media than Mesa Laboratories. MarketBeat recorded 4 mentions for Standard BioTools and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.22 beat Standard BioTools' score of 0.04 indicating that Mesa Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesa Laboratories 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LAB or CTKB?

In the previous week, Standard BioTools and Standard BioTools both had 4 articles in the media. Cytek Biosciences' average media sentiment score of 0.07 beat Standard BioTools' score of 0.04 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Standard BioTools (LAB) Competitors

$0.69 +0.02 (+2.85%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.71 +0.02 (+3.57%)

As of 10/9/2026 07:38 PM Eastern

Compare

LAB vs. CYRX, DNA, PACB, MLAB, and CTKB

Should you buy Standard BioTools stock or one of its competitors? Standard BioTools's main competitors and comparable companies include CryoPort (CYRX), Ginkgo Bioworks (DNA), Pacific Biosciences of California (PACB), Mesa Laboratories (MLAB), and Cytek Biosciences (CTKB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Standard BioTools compare to CryoPort?

Standard BioTools (NASDAQ:LAB) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Standard BioTools has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Comparatively, 9.5% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Standard BioTools has a net margin of 100.36% compared to CryoPort's net margin of -20.05%. CryoPort's return on equity of -7.20% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
CryoPort	-20.05%	-7.20%	-4.30%

In the previous week, Standard BioTools and Standard BioTools both had 4 articles in the media. CryoPort's average media sentiment score of 0.26 beat Standard BioTools' score of 0.04 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Standard BioTools currently has a consensus target price of $1.35, indicating a potential upside of 95.82%. CryoPort has a consensus target price of $18.38, indicating a potential upside of 5.91%. Given Standard BioTools' higher probable upside, equities research analysts clearly believe Standard BioTools is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

CryoPort has higher revenue and earnings than Standard BioTools. CryoPort is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$84.60M	3.20	-$74.90M	$0.22	3.13
CryoPort	$176.18M	4.99	$78.30M	-$0.90	N/A

Summary

CryoPort beats Standard BioTools on 10 of the 15 factors compared between the two stocks.

How does Standard BioTools compare to Ginkgo Bioworks?

Standard BioTools (NASDAQ:LAB) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Standard BioTools has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$84.60M	3.20	-$74.90M	$0.22	3.13
Ginkgo Bioworks	$170.15M	5.13	-$312.76M	-$5.01	N/A

Standard BioTools currently has a consensus target price of $1.35, indicating a potential upside of 95.82%. Ginkgo Bioworks has a consensus target price of $6.33, indicating a potential downside of 51.09%. Given Standard BioTools' stronger consensus rating and higher probable upside, research analysts clearly believe Standard BioTools is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Standard BioTools has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

In the previous week, Ginkgo Bioworks had 16 more articles in the media than Standard BioTools. MarketBeat recorded 20 mentions for Ginkgo Bioworks and 4 mentions for Standard BioTools. Ginkgo Bioworks' average media sentiment score of 0.33 beat Standard BioTools' score of 0.04 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Standard BioTools has a net margin of 100.36% compared to Ginkgo Bioworks' net margin of -259.96%. Standard BioTools' return on equity of -7.57% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Summary

Standard BioTools beats Ginkgo Bioworks on 9 of the 15 factors compared between the two stocks.

How does Standard BioTools compare to Pacific Biosciences of California?

Standard BioTools (NASDAQ:LAB) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Standard BioTools has a net margin of 100.36% compared to Pacific Biosciences of California's net margin of -82.49%. Standard BioTools' return on equity of -7.57% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Standard BioTools has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$84.60M	3.20	-$74.90M	$0.22	3.13
Pacific Biosciences of California	$160.01M	4.53	-$546.38M	-$0.43	N/A

Standard BioTools has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

Standard BioTools currently has a consensus price target of $1.35, suggesting a potential upside of 95.82%. Pacific Biosciences of California has a consensus price target of $1.71, suggesting a potential downside of 26.50%. Given Standard BioTools' higher possible upside, equities analysts clearly believe Standard BioTools is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Pacific Biosciences of California had 8 more articles in the media than Standard BioTools. MarketBeat recorded 12 mentions for Pacific Biosciences of California and 4 mentions for Standard BioTools. Pacific Biosciences of California's average media sentiment score of 0.51 beat Standard BioTools' score of 0.04 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.7% of Standard BioTools shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Standard BioTools beats Pacific Biosciences of California on 9 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Mesa Laboratories?

Standard BioTools (NASDAQ:LAB) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Standard BioTools presently has a consensus target price of $1.35, indicating a potential upside of 95.82%. Mesa Laboratories has a consensus target price of $110.00, indicating a potential downside of 13.73%. Given Standard BioTools' higher possible upside, analysts plainly believe Standard BioTools is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by insiders. Comparatively, 2.8% of Mesa Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Standard BioTools has a net margin of 100.36% compared to Mesa Laboratories' net margin of 1.92%. Mesa Laboratories' return on equity of 22.72% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Mesa Laboratories	1.92%	22.72%	9.82%

In the previous week, Standard BioTools had 1 more articles in the media than Mesa Laboratories. MarketBeat recorded 4 mentions for Standard BioTools and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.22 beat Standard BioTools' score of 0.04 indicating that Mesa Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesa Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesa Laboratories has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$84.60M	3.20	-$74.90M	$0.22	3.13
Mesa Laboratories	$249.13M	2.87	$6.71M	$0.84	151.80

Standard BioTools has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Mesa Laboratories beats Standard BioTools on 9 of the 15 factors compared between the two stocks.

How does Standard BioTools compare to Cytek Biosciences?

Standard BioTools (NASDAQ:LAB) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Standard BioTools has a net margin of 100.36% compared to Cytek Biosciences' net margin of -38.98%. Standard BioTools' return on equity of -7.57% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Standard BioTools has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

In the previous week, Standard BioTools and Standard BioTools both had 4 articles in the media. Cytek Biosciences' average media sentiment score of 0.07 beat Standard BioTools' score of 0.04 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$84.60M	3.20	-$74.90M	$0.22	3.13
Cytek Biosciences	$201.49M	3.50	-$66.54M	-$0.62	N/A

Standard BioTools presently has a consensus price target of $1.35, suggesting a potential upside of 95.82%. Cytek Biosciences has a consensus price target of $5.56, suggesting a potential upside of 2.44%. Given Standard BioTools' higher probable upside, equities analysts plainly believe Standard BioTools is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Standard BioTools beats Cytek Biosciences on 8 of the 15 factors compared between the two stocks.

Get Standard BioTools News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LAB vs. The Competition

Export

Metric	Standard BioTools	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$263.15M	$10.43B	$7.16B	$13.21B
Dividend Yield	N/A	1.45%	2.53%	16.37%
P/E Ratio	3.13	32.42	275.30	26.16
Price / Sales	3.20	106.67	635.97	107.50
Price / Cash	N/A	27.23	76.38	53.09
Price / Book	0.63	6.48	11.22	6.33
Net Income	-$74.90M	$56.67B	$3.50B	$382.15M
7 Day Performance	-7.43%	-1.01%	-0.89%	-1.40%
1 Month Performance	-0.04%	8.89%	-4.42%	-3.47%
1 Year Performance	-46.14%	32.14%	7.03%	1.18%

Standard BioTools Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LAB Standard BioTools	3.4052 of 5 stars	$0.69 +2.8%	$1.35 +95.8%	-49.3%	$263.15M	$84.60M	3.13	389
CYRX CryoPort	2.6224 of 5 stars	$17.62 -2.9%	$18.38 +4.3%	+74.5%	$895.44M	$176.18M	N/A	738	Analyst Upgrade
DNA Ginkgo Bioworks	1.3946 of 5 stars	$13.09 -12.6%	$6.33 -51.6%	-14.7%	$873.74M	$170.15M	N/A	485	News Coverage Gap Up High Trading Volume
PACB Pacific Biosciences of California	1.2559 of 5 stars	$2.71 -5.7%	$1.71 -36.7%	+52.3%	$844.84M	$159.27M	N/A	485	News Coverage Insider Trade Gap Up High Trading Volume
MLAB Mesa Laboratories	1.548 of 5 stars	$136.90 -3.7%	$110.00 -19.7%	+77.9%	$771.30M	$249.13M	163.97	717	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LAB) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Competitors

LAB vs. CYRX, DNA, PACB, MLAB, and CTKB

How does Standard BioTools compare to CryoPort?

Summary

How does Standard BioTools compare to Ginkgo Bioworks?

Summary

How does Standard BioTools compare to Pacific Biosciences of California?

Summary

How does Standard BioTools compare to Mesa Laboratories?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Competitors

LAB vs. CYRX, DNA, PACB, MLAB, and CTKB

How does Standard BioTools compare to CryoPort?

Which has more risk and volatility, LAB or CYRX?

Do insiders and institutionals believe in LAB or CYRX?

Is LAB or CYRX more profitable?

Does the media refer more to LAB or CYRX?

Do analysts prefer LAB or CYRX?

Which has stronger earnings & valuation, LAB or CYRX?

Summary

How does Standard BioTools compare to Ginkgo Bioworks?

Do institutionals and insiders believe in LAB or DNA?

Which has higher earnings and valuation, LAB or DNA?

Do analysts recommend LAB or DNA?

Which has more volatility & risk, LAB or DNA?

Does the media refer more to LAB or DNA?

Is LAB or DNA more profitable?

Summary

How does Standard BioTools compare to Pacific Biosciences of California?

Is LAB or PACB more profitable?

Which has preferable earnings & valuation, LAB or PACB?

Which has more risk and volatility, LAB or PACB?

Do analysts rate LAB or PACB?

Does the media prefer LAB or PACB?

Do insiders & institutionals hold more shares of LAB or PACB?

Summary

How does Standard BioTools compare to Mesa Laboratories?

Do analysts prefer LAB or MLAB?

Do insiders and institutionals believe in LAB or MLAB?

Is LAB or MLAB more profitable?

Does the media refer more to LAB or MLAB?

Which has stronger earnings and valuation, LAB or MLAB?

Which has more risk and volatility, LAB or MLAB?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Is LAB or CTKB more profitable?

Which has more volatility & risk, LAB or CTKB?

Does the media favor LAB or CTKB?

Which has stronger valuation and earnings, LAB or CTKB?

Do analysts rate LAB or CTKB?

Do institutionals and insiders have more ownership in LAB or CTKB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools